Lixivaptan BALANCE study is a 650-patient Phase III, global, multi-center, randomized, placebo-controlled, double-blind, study of lixivaptan for hyponatremia in patients with heart failure. The primary objective is to evaluate the safety and effectiveness of lixivaptan, when compared to the placebo, in increasing serum sodium from baseline in heart failure patients with hyponatremia. In previous studies, lixivaptan improved blood sodium levels, lowered body weight and increased urine volume. Those studies suggest that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with heart failure, Syndrome of Inappropriate Anti-Diuretic Hormone(SIADH), and Liver Cirrhosis with
Blood type (non-human) blood. Two categories of blood groups, human-type and simian-type, have been found in apes and monkeys, and can be tested by methods established for grouping human blood. The rhesus system is named after the rhesus monkey, following experiments by Karl Landsteiner and Alexander S. Wiener, which showed that rabbits, when immunised with rhesus monkey red cells, produce an antibody that also agglutinates the red blood cells of many humans. Data on blood groups of chimpanzees, baboons, and macaques. Two complex chimpanzee blood group systems, V-A-B-D and R-C-E-F systems, proved to be counterparts of the human MNS and Rh-Hr blood group